On April 15, 2021 ArcticZymes Technologies reported its report for the first quarter 2021 on Thursday, 22. April 2021 at 08.30 a.m (Press release, Biotec Pharmacon, APR 15, 2021, View Source [SID1234578075]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Due to the ongoing situation with spread of coronavirus, a number of measures are being implemented to prevent the spread of infection. These measures are being taken to safeguard the health and security of the Company’s shareholders, employees and other stakeholders, and to ensure compliance with applicable national and local restrictions and guidelines. The Company will therefore conduct the presentation only as a webcast over Teams and as a telephone conference.

CEO, Jethro Holter and CFO, Børge Sørvoll will hold the presentation.

Participants who want to participate in the live webcast are asked to send an email to [email protected] for a separate invitation, which will be distributed 1 day prior to the meeting.

Participants who want to participate by telephone should dial in on +47 21 40 24 87 with conference id: 246 245 401#. It will be possible to post questions through the webcast and over the phone after the presentation is finished. The report for the first quarter 2021 will be available on www.newsweb.no and on the company’s homepage www.arcticzymes.com from 07.00 a.m. on 22. April 2021.

On April 15, 2021 Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, reported that the results from the Company’s preclinical studies of its targeted cancer immunotherapeutic agent will be presented as a poster at the New York Academy of Science’s (NYAS) Frontiers in Cancer Immunotherapy Symposium 2021 (Press release, Navidea Biopharmaceuticals, APR 15, 2021, View Source [SID1234578092]). The poster is titled, "Targeted Delivery of Doxorubicin (DOX) to Tumor Associated Macrophages (TAMs) Beneficially Alters the Tumor Immune Microenvironment and Synergizes the Activity of Anti-CTLA4."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In these studies, Navidea’s CD206-targeted therapeutic construct containing doxorubicin linked to its mannosylated dextran backbone (Man-Dox) demonstrated the ability to drive phenotypic change in immune cells towards an activated pro-inflammatory and cell-killing state in vitro and, in conjunction with an approved immunotherapeutic, demonstrated a synergistic effect on tumor growth inhibition in a relevant animal model. The cellular target of Navidea’s Man-Dox agent is the macrophage mannose receptor, CD206. CD206 is expressed on TAMs that play a critical role in regulating the tumor microenvironment and which provide a target for immunotherapies to rally the body’s own immune system in the fight against cancer.

In in vitro studies, treatment of human macrophages with Man-Dox drove macrophages from an immunosuppressive phenotype to an immune stimulatory, pro-inflammatory state. In mouse experiments using the syngeneic CT26 tumor model, Man-Dox, in combination with anti-CTLA4 therapy, showed a significant reduction in tumor growth compared to treatments with either agent alone or with free doxorubicin. Anti-CTLA4 improves anti-tumor immune responses by blocking a check point inhibitor that prevents stimulation of adaptive immune cells by pro-inflammatory macrophages. These new findings support Navidea’s hypothesis that driving the TAM phenotype towards a pro-inflammatory state with Man-Dox in concert with an approved immunotherapy provides a synergistic effect on tumor cell killing. These results demonstrate that Navidea’s targeted Man-Dox construct can improve the efficacy of an existing immunotherapy and support further studies to help define optimal dosing strategies to maximize this synergistic effect.

This year’s conference will be virtual and will take place from May 12th through May 14th. Navidea’s presentation will provide a more detailed look at analysis of these data.

Information regarding registration for the symposium can be found on the NYAS website (link here).

Dr. Michael Rosol, Chief Medical Officer for Navidea, said, "We are delighted by the recognition of the importance of our preclinical results by the symposium committee and the opportunity to present our results at this internationally recognized meeting." Dr. Rosol continued, "This important work demonstrates both a mechanism of action as well as efficacy in relevant in vitro and in vivo model systems. These positive results help lay the foundation for moving forward into an FDA IND application followed by first in human studies."

Jed Latkin, Navidea’s Chief Executive Officer, said, "This is truly a tribute to the many hours of hard work spent by our dedicated team to hone in on a compound that shows remarkable design, enabling this and future pre-clinical clinical work."

On April 15, 2021 Bioneer reported that we will be participating in the Nordic Life Science Days 2021, from April 20th to 23rd (Press release, Bioneer, APR 15, 2021, View Source [SID1234578116]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Nordic Life Science Days is the largest Nordic partnering conference dedicated to the life science industry. This year the event will be in a digital format, where Bioneer will have a virtual booth, where you will find all information about our company and our high quality service.

You can book a meeting with our Sales and Business Development Manager Lovisa Sunesson ([email protected]) on the Nordic Life Science Days platform or contact us via the available online chat.

Moreover you will be able to hear more about our company and specifically our disease modelling in our company presentation featuring Christian Clausen, Chief Scientific Officer at Bioneer.

On April 15, 2021 Juniper Biologics, a science-led healthcare company focused on researching, developing & commercialising novel therapies, reported the appointment of celebrated pharmaceutical executive Raman Singh to the role of Chief Executive (Press release, Juniper Biologics, APR 15, 2021, View Source [SID1234615018]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Juniper Biologics will be focused on researching, developing and commercialising innovative medications in the areas of Oncology, Rare/Orphan Diseases and Gene Therapy. The company is headquartered in Singapore.

Juniper Biologics was founded on a vision to provide the next generation of life-changing treatments for unmet needs focused on specialist therapy areas in which it can make the most difference. The company has the goal of bringing in cutting edge innovation and improving the quality of life of the human race and especially in the wake of the COVID-19 pandemic. Mr Singh’s plan is to do this by focusing exclusively on much neglected therapy areas, specific biological targets and unique formulations with strong value proposition.

‘’The opportunity to lead Juniper Biologics is one I could not pass up. There is a tremendous global need for effective therapies and preventions for Oncology, Rare/Orphan Diseases and Gene Therapy. Success would mean alleviation of a lot of human suffering,’’ said Raman Singh, CEO, Juniper Biologics.

Mr Singh brings over 25 years of experience from the pharmaceutical industry, most recently as CEO of Mundipharma for its Pharmaceutical & Consumer Business where he grew the emerging markets operations from USD$45 million to close to USD$1billion in eight years. Under Mr Singh’s leadership, Mundipharma signed over 60 in-licensing/acquisition deals across multiple therapy areas, covering pharmaceuticals, over-the-counter medicines and fast- moving consumer products.

Prior to joining Mundipharma, Mr. Singh served as Vice-President of commercial operations for emerging markets at GSK. In his role, he oversaw all aspects of the brand’s commercial operations across its emerging markets. Mr. Singh previously held positions at Abbott as the regional director in Australia and New Zealand, and General Manager for Korea, as well as various sales, marketing and strategy positions at Bayer.

More recently during the COVID-19 pandemic, Mr Singh spearheaded R&D efforts to investigate how Mundipharma’ s consumer products could help the developing and developed world impacted by the pandemic, manage the spread of the virus. Laboratory tests with Duke-NUS and other labs worldwide

were initiated to determine the efficacy of certain Betadine products against the spread of the COVID-19 virus.

Mr Singh’s support of Singapore as a strong global business hub has been highlighted across international print and broadcast media. He was also featured as a brand ambassador in the Singapore Tourism Board and Economic Development Board’s POSSIBLE global brand campaign in 2017.

Mr Singh’s many accolades include being named among the Most Powerful People in Healthcare from 2015-2019 by Medicine Maker, Executive of the Year 2017-2019 by SBR Management Excellence Awards and Executive of the Year 2018 at the Scrip Awards.

Mr Singh also sits on the board for Liquidia, a late-stage clinical bio pharmaceutical company focused on the development and commercialisation of novel products. He is the only non-US based Board Member. During his term, he successfully oversaw the IPO in NASDAQ in 2016 as well as the acquisition of RareGen LLC, a portfolio company of PBM Capital Group. A champion of digital healthcare, Mr Singh also sits on the boards of Biofourmis Healthcare and Neuroglee Therapeutics.

On his appointment at Juniper Biologics, Mr Singh added "There is a great unmet need in the treatment of Oncology, Rare/Orphan Diseases and Gene Therapy and it is our responsibility as a company to provide patients with easier access to therapeutic strategies to improve the quality of their lives. Our mission at Juniper Biologics reinforces the drive to deliver new possibilities in treatments, focusing on the best interest of patients and those who care for them.’’

On April 15, 2021 Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, reported that it has commenced an underwritten public offering of its common stock (Press release, Synlogic, APR 15, 2021, View Source [SID1234578076]). All shares of common stock to be sold in the offering will be offered by Synlogic. Synlogic intends to grant the underwriter a 30-day option to purchase up to an aggregate of an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SVB Leerink is acting as sole book-running manager for the offering.

The securities described above are being offered by Synlogic pursuant to its shelf registration statement on Form S-3 (File No. 333-226730) filed with the Securities Exchange Commission (the "SEC") on August 9, 2018 and declared effective by the SEC on August 30, 2018. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at View Source When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may be obtained from SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6105, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities, in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement.